Gillette India (507815) investor relations material

Financial performance and outlook

• Sales for FY ending March 2026 were INR 4,300 crore, flat year-over-year, while profit after tax rose 19% to INR 850 crore, driven by targeted investments and productivity programs.

• Achieved 8% sales growth and 23% PAT growth for FY 2025-26, indexed to a comparable 12-month period due to a fiscal year change.

• Net sales grew at a 10% CAGR and PAT at a 17% CAGR over the past five years, with ROE doubling in the same period.

• Over the past decade, sales and profits have approximately doubled, with a compounded annual profit growth of 8% and net profit margin up 200 basis points.

• Consistent dividend payout record maintained for over three decades, with shareholder value increasing 1.4x over five years and share price more than doubling in the last decade.

Strategic priorities and business developments

• The integrated growth strategy focuses on delivering superiority across product, packaging, brand communication, retail execution, and value, with empowered, agile, and accountable sector business units.

• Investments in data, AI, and digital platforms have enabled real-time consumer insights, operational agility, and AI/ML-driven supply chain optimization.

• Constructive disruption and continuous innovation are central, with multi-year savings plans, automated on-shelf availability checks, and a robust pipeline of new products and upgrades.

• Productivity initiatives delivered INR 86 crore in savings last year and INR 38 crore for FY 25/26, supporting investments in innovation and margin expansion.

• Leadership transitions are managed with a consistent long-term strategy and strong succession planning.

Category and portfolio highlights

• Feminine care and personal healthcare are the core categories, with a focus on superior products at multiple price tiers and high consumer engagement.

• Portfolio expansion in grooming and oral care, with new product launches and enhanced packaging for superior consumer experience.

• Whisper Period Pants and Whisper Nights have driven category growth, with the former selling over 10 crore units and tripling business in the last year.

• Vicks portfolio innovations, such as all-night relief VapoRub and upgraded cough drops, have delivered double-digit growth and increased market share.

• The company leads in both feminine care and healthcare segments, maintaining market leadership despite increased competition from regional and D2C players.